Patents Assigned to Glaxo Group Limited
  • Compounds
    Patent number: 8742099
    Abstract: Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: June 3, 2014
    Assignee: Glaxo Group Limited
    Inventors: Alan David Borthwick, Deirdre Mary Bernadette Hickey, John Liddle, Andrew McMurtrie Mason
  • ANTI-SERUM ALBUMIN BIDING VARIABLE DOMAINS
    Publication number: 20140140996
    Abstract: The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.
    Type: Application
    Filed: January 30, 2014
    Publication date: May 22, 2014
    Applicant: Glaxo Group Limited
    Inventors: Edward COULSTOCK, Elena De Angelis, Haiqun Liu, Oliver Schon
  • Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione
    Patent number: 8716286
    Abstract: The present invention relates to crystalline forms of (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione benzenesulfonate salt and pharmaceutical compositions thereof. Also disclosed are processes for the preparation the above compounds and methods for use thereof.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: May 6, 2014
    Assignee: Glaxo Group Limited
    Inventors: Richard Bellingham, Andrew Mark Buswell, Victoria Ironmonger, Michael Urquhart
  • Dry Powder Inhaler Compositions
    Publication number: 20140116434
    Abstract: Dry powder inhalers comprising a muscarinic acetylcholine receptor antagonist and optionally a beta 2 agonist and/or a corticosteroid for use in the treatment of inflammatory or respiratory tract diseases, such as asthma or COPD.
    Type: Application
    Filed: June 1, 2012
    Publication date: May 1, 2014
    Applicant: GLAXO GROUP LIMITED
    Inventor: Glenn Crater
  • COMPOUNDS
    Publication number: 20140113922
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 24, 2014
    Applicant: GLAXO GROUP LIMITED
    Inventors: Yun JIN, Zehong Wan, Qing Zhang
  • TUMOUR NECROSIS FACTOR RECEPTOR 1 ANTAGONISTS
    Publication number: 20140112929
    Abstract: The invention relates to TNFR1 binding proteins, in particular those which are capable of preventing dimerisation of TNFR1 chains, and to their use in therapy.
    Type: Application
    Filed: June 15, 2012
    Publication date: April 24, 2014
    Applicant: Glaxo Group Limited
    Inventors: Thil Dinuk Batuwangala, Andrew Sanderson, Armin Sepp, Adriaan Allart Stoop
  • Novel Combination of Therapeutic Agents
    Publication number: 20140113888
    Abstract: The present invention is directed to the combination of a muscarinic receptor antagonist and a corticosteroid, and the use of said combination in treating diseases mediated via the M3 muscarinic acetylcholine receptor and/or the glucocorticoid receptor, such as asthma.
    Type: Application
    Filed: June 1, 2012
    Publication date: April 24, 2014
    Applicant: Glaxo Group Limited
    Inventor: Glenn Crater
  • HUMANIZED ANTI-IL-18 ANTIBODIES
    Publication number: 20140105894
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 17, 2014
    Applicant: Glaxo Group Limited
    Inventors: Jonathan Henry ELLIS, Volker Germaschewski, Paul Andrew Hamblin
  • BCMA (CD269/TNFRSF17) - BINDING PROTEINS
    Publication number: 20140105915
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: May 24, 2012
    Publication date: April 17, 2014
    Applicant: Glaxo Group Limited
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Formulation for retinoid-containing soft gelatin capsules
    Patent number: 8697122
    Abstract: A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: April 15, 2014
    Assignee: Glaxo Group Limited
    Inventors: Günter Ditzinger, Bernhard Gabriel, Anne-Hortense Schmitt-Hoffmann, Lutz Wevelsiep
  • Method of treatment based on ATAD2 inhibitors
    Patent number: 8691747
    Abstract: A method of treating autoimmune and inflammatory diseases or conditions in a mammal, such as a human, which comprises the administration of a inhibitor of the bromodomain-containing protein: ATAD2.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: April 8, 2014
    Assignee: Glaxo Group Limited
    Inventors: Laurens Kruidenier, Kevin Lee, David Francis Tough, David Matthew Wilson
  • Fluid dispenser
    Patent number: 8678243
    Abstract: One aspect of the invention provides a component for a fluid dispenser which defines a dosing chamber for a piston member to stroke in and has an end adapted for engaging a fluid outlet of the fluid dispenser or a seal which overlies the fluid outlet to selectively close and open the fluid outlet or seal. Other aspects are disclosed herein.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: March 25, 2014
    Assignees: Glaxo Group Limited, MeadWestVaco Calmar GmbH
    Inventors: James Terence Collins, Thomas Franz Paul Gratzfeld, Heiko Harms, Werner Hertrampf, Richard David Lintern, Gerdhard Niebecker, Allen John Pearson, Paul Kenneth Rand, Karl Heinz Waitz, Karl Gisbert Welp
  • IL-13 binding protein
    Patent number: 8680245
    Abstract: The present invention relates to antigen binding proteins to human IL-13, including anti-IL-13 antibodies and anti-IL-3/anti-IL-4 mAbdAbs, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as asthma or IPF.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: March 25, 2014
    Assignee: Glaxo Group Limited
    Inventors: Claire Ashman, Jonathan Henry Ellis, Paul Andrew Hamblin, Alan Peter Lewis, Martin Anibal Orecchia
  • Anti-serum albumin single variable domains
    Patent number: 8679496
    Abstract: The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: March 25, 2014
    Assignee: Glaxo Group Limited
    Inventors: Edward Coulstock, Elena De Angelis, Haiqun Liu, Oliver Schon
  • MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS
    Publication number: 20140080863
    Abstract: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
    Type: Application
    Filed: October 14, 2013
    Publication date: March 20, 2014
    Applicant: Glaxo Group Limited
    Inventors: Dramane Ibrahim LAINE, Michael R. Palovich, Brent W. McCleland, Christopher E. Neipp, Sonia M. Thomas
  • Manifold for use in Medicament Dispenser
    Publication number: 20140076314
    Abstract: A manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack comprises a body defining a chimney having a chimney inlet and a chimney exit, and defining a chamber having a chamber inlet and a chamber exit, wherein the chimney exit and said chamber inlet lie side-by-side such that when the open blister pocket is positioned adjacent thereto airflow is directed from the chimney exit to the chamber inlet via the open blister pocket, and wherein one or more bleed holes are provided between the chimney and the chamber such that bleed airflow is able to be directed into the chamber to disruptively impact the airflow that transports the entrained medicament powder.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 20, 2014
    Applicant: Glaxo Group Limited
    Inventors: Michael Birsha Davies, Mark Andrew Hailey, Mark Gregory Palmer, Richard Ian Walker
  • Capsule
    Patent number: 8668928
    Abstract: A capsule for a powder has a body which is provided with an internal chamber to hold the powder and first and second openings to an exterior environment. The body is adapted to be displaced from a filling state, in which the first and second openings are placed in fluid communication with one another through the internal chamber thereby enabling an airflow to be created through the body from the second opening to the first opening which is able to entrain powder in the exterior environment into the internal chamber for filling thereof, to a sealing state in which the internal chamber is sealed from the exterior environment so as to retain the powder held therein.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: March 11, 2014
    Assignee: Glaxo Group Limited
    Inventor: Paul Kenneth Rand
  • SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS
    Publication number: 20140058105
    Abstract: Compounds of formula (1) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is 2-methyl-1,3-oxazol-4-yl and R4 and R5 together with the nitrogen atom to which they are attached represents morpholino, process for their preparation, pharmaceutical compositions containing them and their use in medicine.
    Type: Application
    Filed: November 5, 2013
    Publication date: February 27, 2014
    Applicant: Glaxo Group Limited
    Inventor: John Liddle
  • Container
    Patent number: D701456
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: March 25, 2014
    Assignee: Glaxo Group Limited
    Inventors: Stuart John Farley, Andrew Michael Kelly
  • Phenethanolamine derivatives for treatment of respiratory diseases
    Patent number: RE44874
    Abstract: The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: April 29, 2014
    Assignee: Glaxo Group Limited
    Inventors: Philip Charles Box, Diane Mary Coe, Brian Edgar Looker, Panayiotis Alexandrou Procopiou